Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.
“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.
In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.
(No Ratings Yet)
Loading ...You can leave a response, or trackback from your own site.
2 Comments to
“Discontinued ADD drug too risky: FDA”
The REAL reason CYLERT is being taken off the market has NOTHING to do with the issue of liver toxicity. In my opinion, it has to do with the fact that it greatly enhances auditory abilities and sensitivity. As those of us in the Seattle Area who take CYLERT can keenly testify to is when Extremely Low Frequency testing (and other related testing) is taking place here. I’m sure that if it got out to the public and to all eager drug experimenters out there that you can have “super hearing” while taking Cylert, it might upset a few folks. If I elaborate any further, I’m sure I’ll be getting a knock on the door by some nice fellas in black suits. Let the TRUTH be told.
I currently take adderal for attention deficit disorder which is a symptom of my larger condition, which is asperger syndrome. Whether I hear the tones or not isn’t enhanced by my add drugs, but I do hear them. It has to do with the lower frequencies they are using now so that the towers can transmit further. Higher frequencies above our auditory range need to be placed closer together. I get migraines going to the mall near where I live in. I can’t imagine what this could do to the insect population, not to mention the mental wellbeing of mankind. *waits for men in black suits
Join the Conversation! Post a Comment:
Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
